康恩貝(600572.SH):子公司黃蜀葵花總黃酮提取物及口腔貼片藥品註冊獲受理
格隆匯6月16日丨康恩貝(600572.SH)公佈,近日,公司全資子公司杭州康恩貝收到國家藥監局藥品審評中心下發的《受理通知書》,杭州康恩貝申報的黃蜀葵花總黃酮提取物及口腔貼片藥品註冊申請獲國家藥監局受理。
根據技術轉讓有關資料,黃蜀葵花總黃酮口腔貼片的功能主治:清心泄熱。用於心脾積熱所致輕型複發性口腔潰瘍,症見口腔黏膜潰瘍,局部紅腫、灼熱疼痛等。黃蜀葵花總黃酮口腔貼片作為治療口腔潰瘍的中成藥獨家新藥,由於療效確切、安全性好、劑型獨特,具有產品差異性優勢。黃蜀葵花總黃酮提取物為黃蜀葵花總黃酮口腔貼片的原料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.